Off-Label Use Potential With J&J’s Xarelto Not A Factor In Review, FDA Says
In reviewing the approvability of Johnson & Johnson's factor Xa inhibitorXarelto (rivaroxaban), FDA must remain focused on the proposed indication - despite the inclination to factor in the risks associated with potential off-label use, Office of Oncology Drug Products Director Richard Pazdur said
You may also be interested in...
The FDA advisory committee review of Johnson & Johnson's anticoagulant rivaroxaban highlights a recurring regulatory issue for the agency and its expert panels: how to assess newly available data that is not included in the NDA, but could be key to a product's approvability
Surge of interest prompts US FDA to consider how to adjust feedback, including potentially creating a separate team to answer more basic questions.
When the closest you can get to US FDA staff is Webex, the meeting minutes and interactions with the review team project manager take on increased importance, consultants suggest during an Informa-sponsored webinar.